Biotech | April 29, 2022
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
It is expanding the diagnostics business footprint in North East India
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
This facility will design & develop instruments, perform product reliability performance testing and verification
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
The new lab in the industrial town is SRL’s 4th lab in the state of Jharkhand
Covaxin was earlier approved for children 12-18 years of age
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
Subscribe To Our Newsletter & Stay Updated
